Výsledky vyhledávání

P136 Pulmonary hypertension and outcomes in a single-centre IPF cohort

Autor: B Low, Katie Ward, Woods, R K Coker, C Hunt, JT Springett, C Dos Santos, PW Ind, G Hulston

Publikováno v: The nuts and bolts of ILD clinical management.

Introduction Idiopathic pulmonary fibrosis (IPF) often coexists with pulmonary hypertension (PH) and left heart disease (LHD). Estimates of PH prevalence vary, from 8–15% at initial assessment to 30–50% at transplant evaluation. PH conveys increa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9873a953b492953a65982b89dcea7203
https://doi.org/10.1136/thorax-2020-btsabstracts.281

Zobrazit plný text záznamu

Respiratory specialists working in different ways: development of a GP hotline and respiratory support service during the COVID-19 pandemic

Autor: Mohini Parmar, Anna Bokobza, Yasmin Razak, Sarah L. Elkin, V Mak, Loong-Yuan Han, Ernie Wong, Toby Hyde, Kartik Kumar, Joanna L Brown, Katherine Groom, R K Coker

Publikováno v: e92
e88
Future Healthc J

Integration of primary and secondary care for the management of respiratory disease is a long-held ambition. Here, we describe how respiratory specialists at a large NHS trust, working with primary care clinicians in the area, set up a GP hotline and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5f2a3f091b28e713461c33e0d8cb918
http://hdl.handle.net/10044/1/104159

Zobrazit plný text záznamu

Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study

Autor: Philip L. Molyneaux, Maria Molina-Molina, Felix Chua, Siva Mahendran, R K Coker, Pilar Rivera-Ortega, Maria Kokosi, George Margaritopoulos, Alice Packham, Alex West, Suresh Babu, Joanna C. Porter, Nazia Chaudhuri, Elisabeth Bendstrup, Michael Henry, Sharon Sturney, Ewen M Harrison, Tim Wallis, Athol U. Wells, Peter J. M. Openshaw, Louise E. Crowley, Laura Mackay, Elisabetta A. Renzoni, Glenn Hearson, Lisa G. Spencer, Iain A. Stewart, Killian Hurley, Ian Forrest, Diego Castillo Villegas, Sarah Agnew, Thomas M Drake, Simon P. Hart, Gauri Saini, Katherine M.A. O'Reilly, Huzaifa Adamali, Annemarie B Docherty, Jennifer K Quint, J Kenneth Baillie, Muhunthan Thillai, Rachel K. Hoyles, Katie Ward, Melissa Wickremasinghe, Michael A Gibbons, Malcolm G Semple, Davinder Dosanjh, Venerino Poletti, John M. Hutchinson, Helen Parfrey, R. Gisli Jenkins, David R Thickett, Aiden O’Brien, Lucy Howard, Emily Heiden, Michael Kreuter, Shaney L Barratt, Isaric C Investigators, Chris Barber, Anne-Marie Russell, Katherine Groom, S Jones, Stephen Bianchi, Christine A Fiddler, Giulia M. Stella, Anjali Crawshaw, Sarah Haney, Ling-Pei Ho, Helen Stone, William Chang, Peter M. George, Mark Jones, Felix Woodhead

RationaleThe impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established.ObjectivesTo assess outcomes following COVID-19 in patients with ILD versus those without in a contemporaneous age, sex and comorbidity matched

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef8fd371c39f470ec88f1a4be1f856c2

Zobrazit plný text záznamu

M12 52 month follow up of patients with IPF receiving nintedanib via the compassionate use programme

Autor: D Woods, Katie Ward, C Hunt, R K Coker, PW Ind, C Dos Santos, JT Springett

Publikováno v: Real world studies with antifibrotics in IPF.

Introduction In 2015 nintedanib became available on a compassionate use programme (CUP) to patients with idiopathic pulmonary fibrosis (IPF), after the 2014 publication of the INPULSIS trial1 and before receiving National Institute for Health and Car

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4386cb25a67f97369c16f1db8bc027a9
https://doi.org/10.1136/thorax-2019-btsabstracts2019.420

Zobrazit plný text záznamu

P2 The veterans specific activity questionnaire as a patient reported outcome measure in pulmonary vasculitis and interstitial lung disease

Autor: Katie Ward, R K Coker, R Sethi, M Mohamed, Claire L. Shovlin, F Gawecki

Publikováno v: A multi-faceted approach to ILD management.

Introduction and aims Patients with respiratory disease often report activity limitation that is not always adequately or efficiently described by existing physiological parameters or patient reported outcome measure (PROM) tools such as the MRC Dysp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aa202b799af122370bff6ff178170678
https://doi.org/10.1136/thorax-2019-btsabstracts2019.145

Zobrazit plný text záznamu

Frequency of cough versus dyspnoea as the first recorded symptom of idiopathic pulmonary fibrosis

Autor: David Price, Mandy Ow, Jaco Voorham, Ronan Ryan, Andrew Wilson, Victoria Carter, Priyanka Raju, Rupert Jones, Sen Yang, Isha Chaudry, David R Thickett, R K Coker

Publikováno v: Idiopathic interstitial pneumonias.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2e110048aea86f188d90c2f8833e8b76
https://doi.org/10.1183/13993003.congress-2018.pa2922

Zobrazit plný text záznamu

New therapies in IPF: The Hammersmith Hospital experience

Autor: P. W. Ind, R K Coker

Publikováno v: 1.5 Diffuse Parenchymal Lung Disease.

Background: The National Institute for Health and Care Excellence (NICE) approved pirfenidone (PIR) in England & Wales for IPF in April 2013. Nintedanib (NIN) became available more recently on a named patient basis. We review our experience with both

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c52833011480028a535f8aead9bef181
https://doi.org/10.1183/13993003.congress-2016.pa784

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání